专利检索 ap:("Amgen Inc.") AND inv:"LLOYD, David J." 第 1 页

1.

发明公开
METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING ANTAGONISTIC BINDING PROTEINS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR)/GLP-1 RECEPTOR AGONIST FUSION PROTEINS 审中-实审

公开(公告)号：EP4353250A3

公开(公告)日：2024-06-19

申请号：EP24158632.0

申请日：2018-06-20

申请人： Amgen Inc.

发明人： WALKER, Kenneth W. , HOLDER, Jerry Ryan , LLOYD, David J. , LU, Shu-Chen , VENIANT-ELLISON, Murielle M. , STANISLAUS, Shanaka

IPC分类号： C07K16/28 , A61K38/26 , A61P3/10

CPC分类号： A61K38/26 , C07K16/2869 , A61P3/10 , C07K2317/7620130101 , C07K2317/9020130101 , C07K2319/7520130101

摘要： Methods of treating metabolic diseases and disorders using a composition comprising a GLP-1/GIPR antigen binding protein fusion protein are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises the C-terminus of a GLP-1 analog fused to the N-terminus of the light chain variable or heavy chain variable region of an antibody or functional fragment thereof that binds GIPR, optionally with a linker in between.

2.

发明公开
METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING ANTAGONISTIC BINDING PROTEINS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR)/GLP-1 RECEPTOR AGONIST FUSION PROTEINS 审中-实审

公开(公告)号：EP4353250A2

公开(公告)日：2024-04-17

申请号：EP24158632.0

申请日：2018-06-20

申请人： Amgen Inc.

发明人： WALKER, Kenneth W. , HOLDER, Jerry Ryan , LLOYD, David J. , LU, Shu-Chen , VENIANT-ELLISON, Murielle M. , STANISLAUS, Shanaka

IPC分类号： A61K38/26

CPC分类号： A61K38/26 , C07K16/2869

摘要： Methods of treating metabolic diseases and disorders using a composition comprising a GLP-1/GIPR antigen binding protein fusion protein are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the composition comprises the C-terminus of a GLP-1 analog fused to the N-terminus of the light chain variable or heavy chain variable region of an antibody or functional fragment thereof that binds GIPR, optionally with a linker in between.

3.

发明公开
METHOD OF TREATING OR AMELIORATING METABOLIC DISORDERS USING BINDING PROTEINS FOR GASTRIC INHIBITORY PEPTIDE RECEPTOR (GIPR) IN COMBINATION WITH GLP-1 AGONISTS 审中-公开

公开(公告)号：EP3394104A2

公开(公告)日：2018-10-31

申请号：EP16831950.7

申请日：2016-12-21

申请人： Amgen Inc.

发明人： YIE, Junming , SHI, Donghui , LLOYD, David J. , WANG, Jinghong , SIVITS, JR., Glenn N. , VENIANT-ELLISON, Murielle M. , KOMOROWSKI, Renee , AGRAWAL, Neeraj , BATES, Darren L. , CLAVETTE, Brandon C. P. , FOLTZ, Ian N. , HO, Shu-yin , MURAWSKY, Christopher , MIN, Xiaoshan , WANG, Zhulun

IPC分类号： C07K16/28 , A61K38/26 , A61K39/395 , A61P3/10

CPC分类号： C07K16/2869 , A61K9/0019 , A61K38/1703 , A61K38/26 , A61K39/3955 , A61K2039/505 , A61K2039/54 , C07K2299/00 , C07K2317/21 , C07K2317/32 , C07K2317/33 , C07K2317/41 , C07K2317/52 , C07K2317/71 , C07K2317/76 , C07K2317/92 , A61K2300/00

摘要： Methods of treating metabolic diseases and disorders using an antigen binding protein specific for the GIPR polypeptide are provided. In various embodiments the metabolic disease or disorder is type 2 diabetes, obesity, dyslipidemia, elevated glucose levels, elevated insulin levels and diabetic nephropathy. In certain embodiments the antigen binding protein is administered in combination with a GLP-1 receptor agonist.